SMTL ID : 8tzg.1

Structure of C-terminal LRRK2 bound to MLi-2 (I2020T mutant)

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

monomer

Ligands

1 x A1N: (2~{R},6~{S})-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1~{H}-indazol-3-yl]pyrimidin-4-yl]morpholine(Non-covalent)

A1N.1: 17 residues within 4Å: Chain A: L.553, G.556, V.561, R.563, A.572, M.615, E.616, L.617, A.618, S.619, G.621, S.622, H.666, N.667, L.669, A.684, D.685 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:L.553, A:V.561, A:V.561, A:L.617, A:L.669, A:L.669 Hydrogen bonds: A:E.616, A:A.618, A:S.622

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.2: 10 residues within 4Å: Chain A: T.11, G.12, S.13, G.14, K.15, T.16, T.17, T.36, T.120 Ligands: MG.3 9 PLIP interactions: 9 interactions with chain A Hydrogen bonds: A:G.12, A:S.13, A:G.14, A:K.15, A:T.16, A:T.36, A:T.36 Salt bridges: A:K.15, A:K.15

1 x MG: MAGNESIUM ION(Non-covalent)

MG.3: 3 residues within 4Å: Chain A: T.16, T.36 Ligands: GDP.2 1 PLIP interactions: 1 interactions with chain A Metal complexes: A:T.16

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Sanz Murillo, M. et al., Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Sci Adv (2023)

Release Date

2023-12-06

Peptides

Leucine-rich repeat serine/threonine-protein kinase 2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Leucine-rich repeat serine/threonine-protein kinase 2